Past Annual
Meeting Highlights
View Insights and Spotlights from the DTRA 2024 Annual Meeting.
The 2025 Annual Meeting
The 2025 DTRA Annual Meeting (November 6-7, 2025) brought together key leaders advancing the global adoption of innovative methods. Discussions centered on crucial insights from regulatory and governmental bodies regarding the adoption of these methodologies, advancements in stabilizing research practices, and received valuable updates on the integration of DCTs within prominent biopharmaceutical companies and esteemed academic institutions.
2025 Highlights
State of the Industry: Forecasts for Biopharma
Dr. Amir Kalali was joined by Josh Schimmer with Cantor Fitzgerald for an opening Keynote on the State of the Industry. The session unpacked why optimism is rising in biotech by examining shifts in investor behavior, market cycles, innovation trends, global forces, and the influence of AI, while framing where the sector is headed next.
Pharma Spotlights
Our Pharma Spotlight Presentations featured DTRA Members sharing their DCT Journeys, including:
Erica Lawson from Otsuka joined us to share about their first fully virtual trial and the lessons learned along the way.
Jeremy Price from Pfizer joined us to discuss the Pfizer Pledge of getting 60% remote trials across all therapeutic areas in 2022.
Hassan Kadhim from Bristol Myers Squibb shared their journey to climb the DCT mountain and what we can anticipate coming next.
Kim Hawkins from Sanofi discussed how they are disrupting the clinical trial process through DCTs.